中国创新药亮点频出，恒生创新药ETF（159316）、创新药ETF易方达（516080）等助力布局产业发展机遇

Group 1 - The core viewpoint of the news highlights the positive performance of the innovative drug sector in Hong Kong, with significant increases in relevant indices and substantial inflows into ETFs [1][2] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 0.2%, while the CSI Innovative Drug Industry Index increased by 1.3% as of 14:40 [1] - The Hang Seng Innovative Drug ETF (159316) saw over 50 million net subscriptions during the day, and it has attracted more than 1 billion yuan in inflows this month, leading the Hong Kong innovative drug sector [1] Group 2 - Chinese innovative drug companies have made notable achievements at the ESMO conference, with 35 studies selected for oral presentations and 23 for breakthrough abstracts, covering prevalent cancers such as liver cancer, lung cancer, and lymphoma [1] - A significant collaboration between Innovent Biologics and Takeda was announced, involving an upfront payment of 1.2 billion USD and a total deal size of up to 11.4 billion USD, indicating global pharmaceutical companies' recognition of Chinese innovative drugs [1] - Historical analysis suggests that during the Federal Reserve's rate-cutting cycles, the valuation expansion probability for Hong Kong innovative drug assets is high, with a favorable liquidity environment supporting financing and R&D investments for innovative drug companies [1]